This could be achieved by screening for those with higher levels of CRP or circulating inflammatory cytokines like IL-6 or IL-1β, or by recruiting those with depression and/or anxiety with other comorbidities that are themselves associated with high levels of circulating inflammation, like heart disease, diabetes, or neurodegenerative disorders. The gene discussed is IL1B; the disease is depressive symptom measurement.